A TYPE 1 diabetes drug about to be offered on the NHS is the biggest medical breakthrough against the condition since insulin a century ago, say experts. Teplizumab is given through a drip every ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

An engineered stem cell therapy reversed new-onset Type 1 diabetes in mice by shifting the immune system away from attacking ...

The immunotherpay can give children and adults three extra years before they need to use insulin.

Teplizumab, also known as Tzield and made by Sanofi, is approved for children aged 8 and over and adults who have early-stage type 1 diabetes before symptoms appear. It has been proven to slow down ...

Teplizumab is an immunotherapy drug designed to modify the immune system's response. Instead of simply treating symptoms, it ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S. Food and Drug Administration (FDA) to approve Tzield for use in ...

NEW YORK, April 22, 2026 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision by the U.S. Food and ...

Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, today announced enrollment and dosing has ...

The MarketWatch News Department was not involved in the creation of this content. Youth Delegates Living with Type 1 Diabetes and Katie Bone, American Ninja Warrior Champion who Lives with Type 1 ...

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced a $1.5 million, three-year grant to Blue Circle ...